Abstract

This project is aimed at defining the in vivo effects of transfusion with human factor IX concentrates, which are used therapeutically for patients with hemophilia B-factor IX deficiency. The study involves a specific assay for factor IXa, which will be used to assay factor IXa in post-transfusion blood samples. Other assays of activated clotting factors will also be performed on post-transfusion blood samples. The first goal of the study has been to increase the sensitivity of the factor IXa assay in order to detect low levels of factor IXa in blood samples. Futher efforts will be directed toward collecting post-transfusion samples from a number of patients who ordinarily receive factor IX concentrates as part of the therapy of their disease.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL024893-06
Application #
3337884
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1983-09-30
Project End
1986-09-29
Budget Start
1985-09-30
Budget End
1986-09-29
Support Year
6
Fiscal Year
1985
Total Cost
Indirect Cost

  Institution

Name
State University New York Stony Brook
Department
Type
Schools of Medicine
DUNS #
804878247
City
Stony Brook
State
NY
Country
United States
Zip Code
11794

  Publications

Hultin, M B (1991) Fibrinogen and factor VII as risk factors in vascular disease. Prog Hemost Thromb 10:215-41
Hultin, M B; Dattwyler, R J; Lipton, R A (1989) Controlled prospective study of factor IX concentrate therapy and immunodeficiency. Am J Hematol 31:71-2
Hoffman, C J; Miller, R H; Lawson, W E et al. (1989) Elevation of factor VII activity and mass in young adults at risk of ischemic heart disease. J Am Coll Cardiol 14:941-6
Hultin, M B; McKay, J; Abildgaard, U (1988) Antithrombin Oslo: type Ib classification of the first reported antithrombin-deficient family, with a review of hereditary antithrombin variants. Thromb Haemost 59:468-73
Hoffman, C; Shah, A; Sodums, M et al. (1988) Factor VII activity state in coronary artery disease. J Lab Clin Med 111:475-81
Hultin, M B; Abildgaard, U (1987) Antithrombin antigen of high molecular weight associated with neoantigen in hemophilic plasma after factor IX concentrate therapy. Thromb Res 45:175-82
Miller, N; Hultin, M B; Gounder, M et al. (1986) Hereditary antithrombin III deficiency: case report and review of recent therapeutic advances. Am J Hematol 21:215-21
Hoffman, C; Hultin, M B (1986) Factor IX concentrate therapy and thrombosis: relation to changes in plasma antithrombin III. Thromb Res 43:143-51
Hultin, M B (1985) Modulation of thrombin-mediated activation of factor VIII:C by calcium ions, phospholipid, and platelets. Blood 66:53-8
Miller, B C; Hultin, M B; Jesty, J (1985) Altered factor VII activity in hemophilia. Blood 65:845-9